For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A011801

Trial Overview

Official Title

T-DM1 and Tucatinib Compared With T-DM1 Alone In Preventing Relapses In People With High Risk Her2-Positive Breast Cancer

Study Purpose

To compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib.

Diagnosis

Patient has human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and you have already received treatment with chemotherapy and anti-HER2 targeted therapies followed by surgery. At the time of the surgery, cancer was still present in the breast and/or lymph nodes and was removed.

Eligibility

Clinical stage T1-4, N0-3 at diagnose with residual invasive disease post-op.

If HR - negative, residual in breast and/or node, if HR+ positive, residual must be in node.

Micro mets is eligible.

At least 6 cycles chemo pre-op.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

There are two study groups:

  • Usual Approach Group: Patients in this group will get the usual drug used to treat this type of cancer, T-DM1 and a placebo.
  • Study Group: Patients will get a study drug called tucatinib plus the usual drug used to treat this type of cancer, T-DM1.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
A011801
Related Specialties